Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy

International Journal of Molecular Medicine

Volumn 23, Issue 2, 2009, Pages 285-291

  Boidot, Romain ^a   Vegran, Frédérique ^a,b   Lizard Nacol, Sarab ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Breast cancer; Expression; Neoadjuvant chemotherapy; Response; Splice variants; Survivin

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; SURVIVIN; SURVIVIN 2 ALPHA; SURVIVIN 2B; SURVIVIN 3B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ADJUVANT THERAPY; ADVANCED CANCER; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ALTERNATIVE RNA SPLICING; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; METABOLISM; MORTALITY; PREDICTION AND FORECASTING;

ALTERNATIVE SPLICING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS;

EID: 64749105982     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000129     Document Type: Article

References (38)

1. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
2. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
3. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J and Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49, 1998.
4. Xia F and Altieri DC: Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 66: 3392-3395, 2006.
5. Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5: 447-452, 2003.
6. Grossman D, Kim PJ, Blanc-Brude OP, et al: Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 108: 991-999, 2001.
7. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
8. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T and Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7: 602-608, 2000.
9. Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/ DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278: 23130-23140, 2003.
10. Giodini A, Kallio MJ, Wall NR, et al: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62: 2462-2467, 2002.
11. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999.
12. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM and Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24: 1994-2007, 2005.
13. You RI, Chen MC, Wang HW, Chou YC, Lin CH and Hsieh SL: Inhibition of lymphotoxin-beta receptor-mediated cell death by survivin-DeltaEx3. Cancer Res 66: 3051-3061, 2006.
14. Malcles MH, Wang HW, Koumi A, Tsai YH, Yu M, Godfrey A and Boshoff C: Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNFalpha-mediated cell death. Br J Cancer 96: 1659-1666, 2007.
15. Krieg A, Mahotka C, Krieg T, et al: Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86: 737-743, 2002.
16. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T and Inuzuka M: Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314: 902-907, 2004.
17. Caldas H, Honsey LE and Altura RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2: 4-11, 2005.
18. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000.
19. Yamashita S, Masuda Y, Kurizaki T, Haga Y, et al: Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27: 2803-2808, 2007.
20. Knauer SK, Krämer OH, Knösel T, Engels, et al: Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 21: 207-216, 2007.
21. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
22. Hinnis AR, Luckett JC and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96: 639-645, 2007.
23. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS and Kim TY: Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 60: 289-292, 2006.
24. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R and Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 88: 1077-1083, 2003.
25. Brennan DJ, Rexhepaj E, O'Brien SL, et al: Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689, 2008.
26. O'Driscoll L, Linehan R, Kennedy SM, et al: Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-a and MRP-1 mRNAs in breast cancer. Cancer Lett 201: 225-236, 2003.
27. Ryan B, O'Donovan N, Browne B, et al: Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer. Br J Cancer 92: 120-124, 2005.
28. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA and Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52: 1693-1700, 2006.
29. Luporsi E, Vanlemmens L and Coudert B: Six cycles of FEC 100 vs six cycles of epirubicin/docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: results of a randomized phase II trial of GIREC S01. Presented at the 36th Annual ASCO Meeting, Cancer Conf Highlights 4: 2-4, 2000.
30. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP and Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306, 1995.
31. Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P and Lizard-Nacol S: Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61: 13-20, 2000.
32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods 25: 402-408, 2001.
33. Mercatante D and Kole R: Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 85: 237-423, 2000.
34. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9: 1334-1342, 2002.
35. Horwitz SB: Taxol (paclitaxel): mechanisms of action. Ann Oncol 5 (Suppl 6): 3-6, 1994.
36. Knauer SK, Bier C, Schlag P, et al: The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6: 1502-1509, 2007.
37. Ling X, Yang J, Tan D, et al: Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49: 353-361, 2005.
38. Mola G, Vela E, Fernández-Figueras MT, Isamat M and Muñoz-Mármol AM: Exonization of Alu-generated splice variants in the survivin gene of human and non-human primates. J Mol Biol 366: 1055-1063, 2007.